796 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 3
Ji et al.
(7) Cary, S. P. L.; Winger, J. A.; Derbyshire, E. R.; Marletta, M. A. Nitric
oxide signaling: no longer simply on or off. Trends Biochem. Sci.
2006, 31 (4), 231–239.
(8) Moncada, S.; Palmer, R. M.; Higgs, E. A. Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol. ReV. 1991, 43 (2),
109–142.
(9) Domenico, R. Pharmacology of nitric oxide: molecular mechanisms
and therapeutic strategies. Curr. Pharm. Des. 2004, 10 (14), 1667–
1676.
(23) Ji, H.; Tan, S.; Igarashi, J.; Li, H.; Derrick, M.; Marta´sek, P.; Roman,
L. J.; Va´squez-Vivar, J.; Poulos, T. L.; Silverman, R. B. Selective
neuronal nitric oxide synthase inhibitors and the prevention of cerebral
palsy. Ann. Neurol., in press.
(24) Huang, H.; Marta´sek, P.; Roman, L. J.; Masters, B. S.; Silverman,
R. B. Nω-Nitroarginine-containing dipeptide amides. Potent and highly
selective inhibitors of neuronal nitric oxide synthase. J. Med. Chem.
1999, 42 (16), 3147–3153.
(25) Go´mez-Vidal, J. A.; Marta´sek, P.; Roman, L. J.; Silverman, R. B.
Potent and selective conformationally restricted neuronal nitric oxide
synthase inhibitors. J. Med. Chem. 2004, 47 (3), 703–710.
(26) Ji, H.; Go´mez-Vidal, J. A.; Marta´sek, P.; Roman, L. J.; Silverman,
R. B. Confomationally restricted dipeptide amide as potent and
selective neuronal nitric oxide synthase inhibitors. J. Med. Chem. 2006,
49 (21), 6254–6263.
(27) Hah, J.-M.; Roman, L. J.; Marta´sek, P.; Silverman, R. B. Reduced
amide bond peptidomimetics. (4S)-N-(4-Amino-5-[aminoakyl]amino-
pentyl)-N′-nitroguanidines, potent and highly selective inhibitors of
neuronal nitric oxide synthase. J. Med. Chem. 2001, 44 (16), 2667–
2670.
(10) Rosen, G. M.; Tsai, P.; Pou, S. Mechanism of free-radical generation
by nitric oxide synthase. Chem. ReV. 2002, 102 (4), 1191–1199.
(11) Knowles, R. G.; Moncada, S. Nitric oxide synthases in mammals.
Biochem. J. 1994, 298 (2), 249–258.
(12) Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases:
structure, function and inhibition. Biochem. J. 2001, 357 (3), 593–
615.
(13) Roman, L. J.; Marta´sek, P.; Masters, B. S. S. Intrinsic and extrinsic
modulation of nitric oxide synthase activity. Chem. ReV. 2002, 102
(4), 1179–1189.
(28) Hah, J.-M.; Marta´sek, P.; Roman, L. J.; Silverman, R. B. Aromatic
reduced amide bond peptidomimetics as selective inhibitors of neuronal
nitric oxide synthase. J. Med. Chem. 2003, 46 (9), 1661–1669.
(29) (a) Flinspach, M. L.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; Hah,
J.-M.; Go´mez-Vidal, J. A.; Litzinger, E. A.; Silverman, R. B.; Poulos,
T. L. Structural basis for dipeptide amide isoform-selective inhibition
of neuronal nitric oxide synthase. Nat. Struct. Mol. Biol. 2004, 11
(1), 54–59. (b) Flinspach, M.; Li, H.; Jamal, J.; Yang, W.; Huang, H.;
Silverman, R. B.; Poulos, T. L. Structures of the neuronal and
endothelial nitric oxide synthase heme domain with D-nitroarginine-
containing dipeptide inhibitors bound. Biochemistry 2004, 43 (18),
5181–5187. (c) Li, H.; Flinspach, M. L.; Igarashi, J.; Jamal, J.; Yang,
W.; Go´mez-Vidal, J. A.; Litzinger, E. A.; Huang, H.; Erdal, E. P.;
Silverman, R. B.; Poulos, T. L. Exploring the binding conformations
of bulkier dipeptide amide inhibitors in constitutive nitric oxide
synthases. Biochemistry 2005, 44 (46), 15222–15229.
(30) Ji, H.; Li, H.; Flinspach, M.; Poulos, T. L.; Silverman, R. B. Computer
modeling of selective regions in the active site of nitric oxide synthases:
implication for the design of isoform-selective inhibitors. J. Med.
Chem. 2003, 46 (26), 5700–5711.
(31) (a) Wade, R. C.; Goodford, P. J. Further development of hydrogen
bond functions for use in determining energetically favorable binding
sites on molecules of known structure. 1. Ligand and probe groups
with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36
(1), 140–147. (b) Wade, R. C.; Goodford, P. J. Further development
of hydrogen bond functions for use in determining energetically
favorable binding sites on molecules of known structure. 2. Ligand
and probe groups with the ability to form more than two hydrogen
bonds. J. Med. Chem. 1993, 36 (1), 148–156.
(14) Huang, Z.; Huang, P. L.; Panahian, N.; Dalkara, T.; Fishman, M. C.;
Moskowitz, M. A. Effects of cerebral ischemia in mice deficient
in neuronal nitric oxide synthase. Science 1994, 265 (5180), 1883–
1885.
(15) (a) Przedborski, S.; Jackson-Lewis, V.; Yokoyama, R.; Shibata, T.;
Dawson, V. L.; Dawson, T. M. Role of neuronal nitric oxide in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopam-
inergic neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (10),
4565–4571. (b) Hantraye, P.; Brouillet, E.; Ferrante, R.; Palfi, S.;
Dolan, R.; Matthews, R. T.; Beal, M. F. Inhibition of neuronal nitric
oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nat.
Med. 1996, 2 (9), 1017–1021.
(16) Uehara, T.; Nakamura, T.; Yao, D.; Shi, Z. Q.; Gu, Z.; Ma, Y.; Masliah,
E.; Nomura, Y.; Lipton, S. A. S-Nitrosylated protein-disulphide
isomerase links protein misfolding to neurodegeneration. Nature 2006,
441 (7092), 513–517.
(17) Kim, S. F.; Huri, D. A.; Snyder, S. H. Inducible nitric oxide synthase
binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005,
310 (5756), 1966–1970.
(18) (a) Huang, P. L.; Huang, Z.; Mashimo, H.; Bloch, K. D.; Moskowitz,
M. A.; Bevan, J. A.; Fishman, M. C. Hypertension in mice lacking
the gene for endothelial nitric oxide synthase. Nature 1995, 377 (6546),
239–242. (b) Endres, M.; Laufs, U.; Liao, J. K.; Moskowitz, M. A.
Targeting eNOS for stroke protection. Trends Neurosci. 2004, 27 (5),
283–289. (c) Braam, B.; Verhaar, M. C. Understanding eNOS for
pharmacological modulation of endothelial function: a translational
view. Curr. Pharm. Des. 2007, 13 (17), 1727–1740.
(19) (a) Salerno, L.; Sorrenti, V.; Di Giacomo, C.; Romeo, G.; Siracusa,
M. A. Progress in the development of selective nitric oxide synthase
(NOS) inhibitors. Curr. Pharm. Des. 2002, 8 (3), 177–200. (b) Erdal,
E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Ji, H.; Silverman, R. B.
Selective neuronal nitric oxide synthase inhibitors. Curr. Top. Med.
Chem. 2005, 5 (7), 603–624. (c) Tafi, A.; Angeli, L.; Venturini, G.;
Travagli, M.; Corelli, F.; Botta, M. Computational studies of competi-
tive inhibitors of nitric oxide synthase (NOS) enzymes: towards the
development of powerful and isoform-selective inhibitors. Curr. Med.
Chem. 2006, 13 (16), 1929–1946.
(32) Miranker, A.; Karplus, M. Functionality maps of binding sites: a
multiple copy simultaneous search method. Proteins 1991, 11 (1), 29–
34.
(33) (a) Bo¨hm, H.-J. The computer program LUDI: a new method for the
de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992,
6 (1), 61–78. (b) Bo¨hm, H.-J. LUDI: rule-based automatic design of
new substitutents for enzyme inhibitor leads. J. Comput.-Aided Mol.
Des. 1992, 6 (6), 593–606.
(34) Lawton, G. R.; Ji, H.; Silverman, R. B. Remote protection prevents
unwanted cyclizations with 2-aminopyridines. Tetrahedron Lett. 2006,
47 (34), 6113–6115.
(20) Vallance, P.; Leiper, J. Blocking NO Synthesis: how, where and why?
Nat. ReV. Drug DiscoVery 2002, 1 (12), 939–950.
(35) Igarashi, J.; Li, H.; Jamal, J.; Ji, H.; Fang J.; Silverman, R. B.; Poulos,
T. L. Crystal structures of constitutive nitric oxide synthases in complex
with de novo designed inhibitors. J. Med. Chem., submitted.
(36) Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar
surface area as a sum of fragment-based contributions and its
application to the prediction of drug transport properties. J. Med. Chem.
2000, 43 (20), 3714–3717.
(21) (a) Silverman, R. B.; Huang, H.; Marletta, M. A.; Marta´sek, P.
Selective inhibition of neuronal nitric oxide synthase by Nω-nitroargi-
nine-and phenylalanine-containing dipeptides and dipeptide esters.
J. Med. Chem. 1997, 40 (18), 2813–2817. (b) Zhang, H. Q.; Fast, W.;
Marletta, M. A.; Marta´sek, P.; Silverman, R. B. Potent and selective
inhibition of neuronal nitric oxide synthase by Nω-propyl-L-arginine.
J. Med. Chem. 1997, 40 (24), 3869–3870.
(37) BioByte Corp., 201 W. Fourth Street, Suite 204, Claremont, CA 91711
(22) (a) Crane, B. R.; Arvai, A. S.; Ghosh, D. K.; Wu, C.; Getzoff, E. D.;
Stuehr, D. J.; Tainer, J. A. Structure of nitric oxide synthase oxygenase
dimer with pterin and substrate. Science 1998, 279 (5359), 2121–2126.
(b) Raman, C. S.; Li, H.; Marta´sek, P.; Kral, V.; Masters, B. S.; Poulos,
T. L. Crystal structure of constitutive endothelial nitric oxide synthase:
a paradigm for pterin function involving a novel metal center. Cell
1998, 95 (7), 939–950. (c) Fischmann, T. O.; Hruza, A.; Niu, X. D.;
Fossetta, J. D.; Lunn, C. A.; Dolphin, E.; Prongay, A. J.; Reichert, P.;
Lundell, D. J.; Narula, S. K.; Weber, P. C. Structural characterization
of nitric oxide synthase isoforms reveals striking active-site conserva-
tion. Nat. Struct. Biol. 1999, 6 (3), 233–242. (d) Li, H.; Shimizu, H.;
Flinspach, M.; Jamal, J.; Yang, W.; Xian, M.; Cai, T.; Wen, E. Z.;
Jia, Q.; Wang, P. G.; Poulos, T. L. The novel binding mode of N-alkyl-
N′-hydroxyguanidine to neuronal nitric oxide synthase provides
mechanistic insights into NO biosynthesis. Biochemistry 2002, 41 (47),
13868–13875.
(http://www.biobyte.com/).
(38) ACD/log D Suite: Advanced Chemistry Development Inc., 110 Yonge
Street, 14th floor, Toronto, Ontario, Canada M5C 1T4 (http://
www.acdlabs.com).
(39) Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.;
Howe, T.; Vianello, R. ; MetaSite: understanding metabolism in human
cytochromes from the perspective of the chemist. J. Med. Chem. 2005,
48 (22), 6970–6979.
(40) Garcin, E. D.; Arvai, A. S.; Rosenfeld, R. J.; Kroeger, M. D.; Crane,
B. R.; Andersson, G.; Andrews, G.; Hamley, P. J.; Mallinder, P. R.;
Nicholls, D. J.; St-Gallay, S. A.; Tinker, A. C.; Gensmantel, N. P.;
Mete, A.; Cheshire, D. R.; Connolly, S.; Stuehr, D. J.; Aberg, A.;
Wallace, A. V.; Tainer, J. A.; Getzoff, E. D. Anchored plasticity opens
doors for selective inhibitor design in nitric oxide synthase. Nat. Chem.
Biol. 2008, 4 (11), 700–707.